Market Overview

Morgan Stanley, Canaccord Genuity Out Bullish On Forty Seven: 'A Significant Lead'

Share:
Morgan Stanley, Canaccord Genuity Out Bullish On Forty Seven: 'A Significant Lead'
Related
51 Biggest Movers From Yesterday
Benzinga's Top Upgrades, Downgrades For November 30, 2018
XPO, LLNW and TLRD among notable midday movers (Seeking Alpha)

Forty Seven Inc. (NASDAQ: FTSV), a clinical-stage immuno-oncology companhy that went public in June, picked up two sell-side bulls Monday. 

The Analysts

Morgan Stanley analyst Matthew Harrison initiated Forty Seven with an Overweight rating and $25 price target.

Canaccord Genuity analyst Arlinda Lee initiated coverage of Forty Seven with a Buy and $22 price target. 

The Thesis

Forty Seven is developing a pipeline of drug candidates that activate the innate immune system, Cannacord's Lee said in a Monday initiation note. (See the analyst's track record here.)

The agent 5F9 is an antibody that fights against CD47 and can diminish a tumor’s ability to evade attack; CD47 is present in numerous cases of cancer, the analyst said. 

Based on the data for 5F9 in diffuse large B-cell lymphoma, Canaccord estimates the candidate is worth $10 per share. In follicular lymphoma and ovarian cancer, Canaccord estimates 5F9 is worth $3 per share.

The candidate shows both strong single-agent activity as well as activity in conjunction with other anti-cancer agents, said Morgan Stanley's Harrison. (See the analyst's track record here.)

The use of this agent could help with cancer research and development in the future, the analyst said. 

"While many other companies are trying to develop anti-CD47 antibodies, Forty Seven has a significant lead given it has addressed a key on-target tolerability issue (anemia) and has IP protecting its strategy to reduce that side effect," he said. "Further, Forty Seven has multiple mature clinical datasets potentially placing it years ahead of competitor."

Price Action

Forty Seven shares were trading up 3.48 percent at $16.35 at the time of publication Monday afternoon. 

Related Links

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs

Merck Announces Plans To Cut Drug Prices

Latest Ratings for FTSV

DateFirmActionFromTo
Nov 2018H.C. WainwrightInitiates Coverage OnBuy
Oct 2018Morgan StanleyMaintainsOverweightOverweight
Jul 2018OppenheimerInitiates Coverage OnOutperform

View More Analyst Ratings for FTSV
View the Latest Analyst Ratings

Posted-In: Canaccord Genuity Morgan StanleyBiotech Price Target Initiation Top Stories Analyst Ratings General Best of Benzinga

 

Related Articles (FTSV)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
DLTRBernsteinUpgrades0.0
CNPUBSUpgrades34.0
UGIUBSDowngrades63.0
ATOUBSDowngrades106.0
CSCONomuraDowngrades50.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

A Preview Of Astec Industries Q2 Earnings

Biogen Q2 Earnings Preview